<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>shareholdersunite.com &#187; Biotech</title>
	<atom:link href="http://shareholdersunite.com/category/biotech/feed/" rel="self" type="application/rss+xml" />
	<link>http://shareholdersunite.com</link>
	<description>Opportunities in smallcaps</description>
	<lastBuildDate>Tue, 07 Feb 2012 10:50:42 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
	<!-- added to the content header -->	<item>
		<title>Biotechs ready to rock</title>
		<link>http://shareholdersunite.com/2011/02/17/biotech/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biotech</link>
		<comments>http://shareholdersunite.com/2011/02/17/biotech/#comments</comments>
		<pubDate>Thu, 17 Feb 2011 03:02:36 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotech]]></category>

		<guid isPermaLink="false">http://shareholdersunite.com/2011/02/17/biotech/</guid>
		<description><![CDATA[And roll..From Chartadvisor: Commentary: The markets continue to head higher despite corrections among&#160;some recent high fliers like F5 Networks (Nasdaq:FFIV) and&#160;Motricity (Nasdaq:MOTR). While participation in this rally has narrowed a bit, there are still many sectors that appear healthy. Traders that have been able to make the adjustment and follow the money as it rotates [...]]]></description>
		<wfw:commentRss>http://shareholdersunite.com/2011/02/17/biotech/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What to buy? Gamble with biotech stocks II</title>
		<link>http://shareholdersunite.com/2009/05/25/biotech-stocks-2/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biotech-stocks-2</link>
		<comments>http://shareholdersunite.com/2009/05/25/biotech-stocks-2/#comments</comments>
		<pubDate>Mon, 25 May 2009 16:06:12 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[ABIO]]></category>
		<category><![CDATA[ACUS]]></category>
		<category><![CDATA[ADLS]]></category>
		<category><![CDATA[BDSI]]></category>
		<category><![CDATA[DDSS]]></category>
		<category><![CDATA[HEB]]></category>
		<category><![CDATA[SPPI]]></category>
		<category><![CDATA[TSPT]]></category>
		<category><![CDATA[VION]]></category>
		<category><![CDATA[VNDA]]></category>

		<guid isPermaLink="false">http://shareholdersunite.com/?p=1168</guid>
		<description><![CDATA[Here is the portfolio approach we promised in the last article. The possible gains are such that if even just a couple make it through the next regulatory hurdle, the whole portfolio will win out&#8230; Vanda Pharma: An Extreme FDA Trade That Paid; 9 More to Go Mike Havrilla Shares of Vanda Pharma (NASDAQ:VNDA) soared [...]]]></description>
		<wfw:commentRss>http://shareholdersunite.com/2009/05/25/biotech-stocks-2/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>What to buy? Gamble on biotech stocks</title>
		<link>http://shareholdersunite.com/2009/05/25/biotech-stocks/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biotech-stocks</link>
		<comments>http://shareholdersunite.com/2009/05/25/biotech-stocks/#comments</comments>
		<pubDate>Mon, 25 May 2009 15:42:21 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[BCRX]]></category>

		<guid isPermaLink="false">http://shareholdersunite.com/?p=1167</guid>
		<description><![CDATA[The regulatory approval process for new drugs is Byzantine, lengthy, and unpredictable. Single stocks are, for outsiders at least (even insiders can be surprised), almost pure bets. But one can still profit from the usual fact that the winnings are often much larger than the possible losses&#8230; Such an approach would involve taking a portfolio [...]]]></description>
		<wfw:commentRss>http://shareholdersunite.com/2009/05/25/biotech-stocks/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	<!-- added to the content footer --></channel>
</rss>

<!-- Performance optimized by W3 Total Cache. Learn more: http://www.w3-edge.com/wordpress-plugins/

Served from: www.shareholdersunite.com @ 2012-02-07 06:22:11 -->
